BioNano Hits Scientific Milestone: 100 Unique Species Genetically Mapped and Analyzed
BioNano expands commercial access of the Irys System to Japan
SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- BioNano Genomics announced today that it has mapped and analyzed more than 100 unique species, including human, plant, animal and microbe, on the Irys® System. BioNano's Irys System creates a high-resolution genome map for the precise assembly of DNA sequences, completion of large genomes and understanding of genomic structural variation.
Achieving this milestone demonstrates the compatibility of the Irys System across a variety of species and highlights the importance of a comprehensive understanding of structural variations for genomic analysis and research.
"BioNano's Irys System resolves the variant information generated by next generation sequencing platforms, as well as reveals new, previously undetected variants in days not months," said Han Cao, Ph.D., founder and chief scientific officer of BioNano Genomics. "Scientists are using the Irys System to complete their genomes and perform more comprehensive analysis to enable genomic discovery."
To date, 32 institutions, located in the United States, Europe and Asia Pacific, already own an Irys System. To further support this growth, BioNano recently expanded its existing Asia-Pacific distribution to Japan, in partnership with AS ONE Corporation.
New features in development for the Irys System and recent research will be presented at the 16th Annual Advances in Genome Biology and Technology (AGBT) meeting, which will be held February 25 to 28 in Marco Island, Florida. BioNano will be hosting presentations during the coffee breaks in Suite #183. To request a private meeting during AGBT 2015, email [email protected].
About Irys
Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip® to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays™ where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long "reads" ranging from hundreds of kilobases to a megabase, where the sample's valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.
About BioNano Genomics
Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company's platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.
Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
SOURCE BioNano Genomics
Related Links
http://www.bionanogenomics.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article